In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Melanie Senior

Advertisement
Set Alert for Articles By Melanie Senior

Latest From Melanie Senior

To Get Pricing Right, Pharma Must Understand Payer Behavior, Trump Or No Trump

When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.

Reimbursement Pricing Debate

Personalized Medicine: What's Your Strategy?

Free content: Personalized medicine is upending the business of health care. In March, In Vivo will focus on exploring this new landscape. There is no single "right" route for companies to follow, but pharma, payers and other stakeholders need to find a path because the forces driving personalized medicine are global, and unstoppable.

BioPharmaceutical Growth

Europe’s Payers Bake Indication-Specific Pricing Into Benefit Assessments

European countries haven’t grappled with indication-specific pricing, mostly because they haven’t had to.

BioPharmaceutical

Pricing By Indication Takes Hold, Despite Hurdles

Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.

Market Access Pricing Strategies

Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows

The Institute for Clinical and Economic Review has invited feedback on its methodology for calculating a drug's recommended price range. Industry response has been critical, but pharma can no longer afford to merely oppose value frameworks. It needs to create strategies for a world in which such frameworks are a permanent and influential part of the pricing and reimbursement landscape.

Pricing Strategies Market Access

DrugAbacus Gains Money, Sophistication

In February 2016, the non-profit Laura and John Arnold Foundation donated $4.7 million to Memorial Sloan Kettering Cancer Center’s Evidence Driven Drug Pricing Project, home of the DrugAbacus.

BioPharmaceutical
See All
Advertisement
UsernamePublicRestriction

Register